6月23日，康方生物盘中上涨3.44%，报85.85港元，成交额1.15亿港元。消息面上，公司股价前一交易日一度跌至82.5港元逼近52周低点82.85港元，技术面超卖修复叠加产业资本护盘共同触发反弹。此前公司董事会批准最多2亿港元回购计划及管理层拟增持合计不超过5000万港元。同时兴业证券最新研报维持"增持"评级，认为依沃西HARMONi-6 OS数据具里程碑意义，预计其2033年前有望实现150亿美元以上收入，基本面支撑信号明确。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.